A5077983721- Immune Cell Function and Interaction
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Blood groups and transfusion
- Virus-based gene therapy research
- Cancer Research and Treatments
- Neuroblastoma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- CRISPR and Genetic Engineering
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Cell Biotech (South Korea)
2021
Yong In University
2018
Korea Advanced Institute of Science and Technology
2013
Bio-Medical Science (South Korea)
2013
Natural killer (NK) cells with mismatched cell immunoglobulin-like receptor-ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. Ex vivo-expanded highly activated NK (MG4101) had generated under good manufacturing practice conditions, which demonstrated potent anticancer activity vitro vivo preclinical studies. The current phase I clinical trial was designed to evaluate safety possible repetitive administrations MG4101 derived from random unrelated healthy...
Ex vivo-expanded, allogeneic natural killer (NK) cells can be used for the treatment of various types cancer. In NK cell therapy, from healthy donors must expanded in order to obtain a sufficient number highly purified, activated cells. present study, we established simplified and efficient method large-scale expansion activation under good manufacturing practice (GMP) conditions. After single step magnetic depletion CD3(+) T cells, depleted peripheral blood mononuclear (PBMCs) were...
Abstract As recent advancements in the chimeric antigen receptor-T cells have revolutionized way blood cancers are handled, potential benefits from producing off-the-shelf, standardized immune entail need for development of allogeneic cell therapy. However, host rejection driven by HLA disparity adoptively transferred T remains a key obstacle to universal donor To evade HLA-mediated rejection, we attempted eliminate cell’s through CRISPR/Cas9 gene editing system. First, screened 60 gRNAs...
Introduction Under the hypothesis that early natural killer cell infusion (NKI) following haploidentical stem transplantation (haplo-SCT) will reduce relapse in post-transplant period, we conducted a pilot study to evaluate safety and feasibility of NKI haplo-SCT children with recurrent neuroblastoma who failed previous tandem high-dose chemotherapy autologous SCT. Methods We used 131I-metaiodobenzylguanidine cyclophosphamide/fludarabine/anti-thymocyte globulin regimen for conditioning...
Fewer reports have been published regarding hepatectomy patients with solitary hepatocellular carcinoma (HCC) who received immunotherapeutic agents as adjuvant therapy. We evaluated the safety and efficacy of ex vivo-expanded allogenic natural killer (NK) cells in those modified International Union Against Cancer (UICC) stage T3.From August 2014 to October 2015, five underwent hepatic resection NK cells. Patients rounds (2-3×107 cells/kg) at postoperative 4, 6, 8, 12, 16 weeks. This study is...
<p>Supplementary Figure S1. Clinical treatment protocol; Supplementary S2. Characterization of ex vivo-expanded NK cells; S3. Analysis donor KIR genotype and clinical outcome; S4. Kinetics cells in the peripheral blood recipients; S5. NKG2D expression on T patients' blood.</p>
<div>Abstract<p>Natural killer (NK) cells with mismatched cell immunoglobulin-like receptor–ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. <i>Ex vivo</i>–expanded highly activated NK (MG4101) had generated under good manufacturing practice conditions, which demonstrated potent anticancer activity <i>in vitro</i> vivo</i> preclinical studies. The current phase I clinical trial was designed to evaluate safety...
<p>Supplementary Figure S1. Clinical treatment protocol; Supplementary S2. Characterization of ex vivo-expanded NK cells; S3. Analysis donor KIR genotype and clinical outcome; S4. Kinetics cells in the peripheral blood recipients; S5. NKG2D expression on T patients' blood.</p>
<div>Abstract<p>Natural killer (NK) cells with mismatched cell immunoglobulin-like receptor–ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. <i>Ex vivo</i>–expanded highly activated NK (MG4101) had generated under good manufacturing practice conditions, which demonstrated potent anticancer activity <i>in vitro</i> vivo</i> preclinical studies. The current phase I clinical trial was designed to evaluate safety...
Abstract Mesothelin (MSLN) is an antigen overexpressed in several malignancies, including mesothelioma and ovarian pancreatic adenocarcinoma. It has been studied as a marker for diagnosis target immunotherapy. Here, we adopted bispecific antibody format recruiting cytotoxic T cells to kill tumor cells. MG1122 novel, whole IgG-like which recognizes CD3 on MSLN induced effective killing of MSLN-expressing This response was associated with robust activation shown by nuclear factor activated...
e14500 Background: Engaging T cells to attack tumors is a new class of immunotherapy. Tumor-specific cell-engaging antibodies have an ability redirect and activate target tumor cells, thereby amplifying anti-tumor effects. Mesothelin (MSLN) 40 kDa GPI-anchored glycoprotein which highly expressed in several cancers, including mesotheliomas, pancreatic cancer, lung ovarian while at relatively low levels normal mesothelial the pleura, peritoneum pericardium. Methods: We developed MG1122...